(1) Schirren J, Schirren M, Lampl L, Sponholz S. Surgery for pulmonary metastases: quo vadis? Eur J Cardiothorac Surg 2017 March 1;51(3):408-10.
(2) Fiorentino F, Hunt I, Teoh K, Treasure T, Utley M. Pulmonary metastasectomy in colorectal cancer: a systematic review and quantitative synthesis. J R Soc Med 2010 February;103(2):60-6.
(3) Pastorino U, Buyse M, Friedel G, Ginsberg RJ, Girard P, Goldstraw P et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg 1997;113:37-49.
(4) Aberg T, Malmberg KA, Nilsson B, Nou E. The effect of metastasectomy: fact or fiction? Ann Thorac Surg 1980 October;30(4):378-84.
(5) Barton MK. Metastasectomy on the rise across several cancer types. CA Cancer J Clin 2015 May;65(3):163-4.
(6) Bartlett EK, Simmons KD, Wachtel H, Roses RE, Fraker DL, Kelz RR et al. The rise in metastasectomy across cancer types over the past decade. Cancer 2015 March 1;121(5):747-57.
(7) Jawed I, Wilkerson J, Prasad V, Duffy AG, Fojo T. Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis. JAMA Oncol 2015 September 1;1(6):787-95.
(8) Gonzalez M, Poncet A, Combescure C, Robert J, Ris HB, Gervaz P. Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol 2013 February;20(2):572-9.
(9) Jeffery M, Hickey BE, Hider PN, See AM. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2016 November 24;11:CD002200.
(10) Mokhles S, Macbeth F, Farewell V, Fiorentino F, Williams NR, Younes RN et al. Meta-analysis of colorectal cancer follow-up after potentially curative resection. Br J Surg 2016 September;103(10):1259-68.
(11) Aberg T. Selection mechanisms as major determinants of survival after pulmonary metastasectomy. Ann Thorac Surg 1997 March;63(3):611-2.
(12) Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are randomised trials unnecessary? Picking signal from noise. BMJ 2007 February 17;334(7589):349-51.
(13) Monson K, Treasure T, Brew-Graves C, Jenkins V, Fallowfield L.
Surveying patients' views on trial information provision and decision making using the 'Accept/Decline' clinical trials questionnaire . Trials 2017;18 (Suppl 1):24.
(14) Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997 July;34(3 Suppl 2):13-9.
(15) Cella D. FACIT questionnaire specifics manual. 24-8-2005. 24-8-2005.
Ref Type: Pamphlet
(16) Marteau TM, Bekker H. The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). Br J Clin Psychol 1992 September;31 ( Pt 3):301-6.
(17) EuroQol--a new facility for the measurement of health-related quality of life. Health Policy 1990 December;16(3):199-208.
(18) Liang K, Zeger S. Longitudinal data analysis using generalized linear models. Biometrika 2018;73(1):13-22.
(19) Cella D, Nichol MB, Eton D, Nelson JB, Mulani P. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health 2009 January;12(1):124-9.
(20) Eton D, Yost K. Minimally important differences on the functional assessment of chronic illness therapy instruments. In FACIT Manual Version 4. Section 4 - Validity and Interpretation. Doc 116. 2005. 2005.
Ref Type: Pamphlet
(21) Cox DR. Regression models and life-table. Journal of the Royal Statistical Society B 1972;34:187-220.
(22) Farewell DM. Marginal analyses of longitudinal data with an informative pattern of observations. Biometrika 2010;97(1):65-78.
(23) Gonzalez M, Robert JH, Halkic N, Mentha G, Roth A, Perneger T et al. Survival after lung metastasectomy in colorectal cancer patients with previously resected liver metastases. World J Surg 2012 February;36(2):386-91.
(24) Gyawali B, Shimokata T, Honda K, Ando Y. Reporting harms more transparently in trials of cancer drugs. BMJ 2018 November 1;363:k4383.
(25) Treasure T, Baum M. An approach to randomization into surgical clinical trials. Br J Surg 2017 January;104(1):11-2.
(26) Prasad V, Vandross A, Toomey C, Cheung M, Rho J, Quinn S et al. A decade of reversal: an analysis of 146 contradicted medical practices. Mayo Clin Proc 2013 August;88(8):790-8.
(27) Veronesi U, Saccozzi R, Del Vecchio M, Banfi A, Clemente C, De Lena M et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 1981 July 2;305(1):6-11.
(28) Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011 August;12(8):763-72.
(29) Horton R. Surgical research or comic opera: questions, but few answers. Lancet 1996 April 13;347(9007):984-5.
(30) Chang J, Senan S, Smit ERJ. Surgery versus SABR for resectable non-small cell lung cancer. Lancet Oncology 2015;16:e374-e375.